ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ¾ÈÁ¤µÈ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 4.4%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 24¾ï 9,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ÀÎÁöµµ Çâ»ó Ä·ÆäÀÎ È®´ë, ´ë»ç ÀÌ»ó »ç·Ê ¼ö Áõ°¡, ¿ø°ÝÀÇ·á ä¿ë È®´ë, ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇコÄɾî ÅõÀÚ Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿Çâ¿¡´Â Áø´ÜÀÇ ±â¼úÀû Áøº¸, À¯ÀüÀÚ Ä¡·á °³¹ß, ´ë»ç Ä¡·á Çõ½Å, ÇコÄɾ¼ AI ÅëÇÕ, ½Å±Ô Ä¡·áÁ¦ âÃâ µîÀÌ Æ÷ÇԵ˴ϴÙ.
À¯Àü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯Àü ÁúȯÀº °³ÀÎÀÇ DNA º¯À̳ª ÀÌ»ó¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â º´ÅÂÀ̸ç, À¯ÀüµÇ´Â °æ¿ìµµ ÀÖ°í ÀÚ¿¬ÀûÀ¸·Î ¹ß»ýÇÏ´Â °æ¿ìµµ ÀÖ¾î °Ç°°ú °³¹ß¿¡ ¿µÇâÀ» ÁÝ´Ï´Ù. À¯Àü Áúȯ Áõ°¡ÀÇ ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¿¼º À¯ÀüÀÚÀÇ µ¹¿¬º¯À̸¦ ¹°·Á¹ÞÀ» °¡´É¼ºÀ» ³ôÀÌ´Â ±ÙģȥÀÔ´Ï´Ù. ÀÌ´Â °áÇÔÀÌ ÀÖ´Â À¯ÀüÀÚ¸¦ ºÎ¸ð·ÎºÎÅÍ ¹°·Á¹ÞÀ¸¸é¼ ¹ß»ýÇØ À¯Àü ÁúȯÀÇ À§ÇèÀ» ÇöÀúÈ÷ ³ôÀÔ´Ï´Ù. ÇÁ·ÎÇǿ»êÇ÷ÁõÀº ´ë»ç ºÒ±ÕÇü¿¡ ´ëóÇϰí ȯÀÚÀÇ Àü±Í¸¦ °³¼±Çϴ ǥÀûÄ¡·á¸¦ Á¦°øÇÔÀ¸·Î½á À¯Àü Áúȯ °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 7¿ù ¹Ì±¹ ºñ¿µ¸®´ÜüÀÎ ³¶Æ÷¼º¼¶À¯Áõ(CF)Àç´ÜÀÌ ¹ßÇ¥ÇÑ º¸°í¼¿¡ µû¸£¸é ³¶Æ÷¼º¼¶À¯Áõ À¯º´·üÀº Áõ°¡Çϰí ÀÖÀ¸¸ç, 2022³â¿¡´Â ¹Ì±¹¿¡¼ ¾à 4¸¸ ¸íÀÇ ¾î¸°ÀÌ¿Í ¼ºÀÎÀÌ ÀÌȯµÇ¾ú°í, Àü ¼¼°èÀûÀ¸·Î´Â 10¸¸ 5õ ¸í ÀÌ»óÀÌ Áø´ÜµÇ¾ú½À´Ï´Ù. ±× °á°ú À¯Àü ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀåÀÇ È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Áúº´ÀÇ À¯ÀüÀû ¿øÀÎÀ» Á÷Á¢ Ç¥ÀûÀ¸·Î ÇÏ´Â Çõ½ÅÀûÀÎ mRNA ±â¹Ý Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. mRNA Ä¡·á¹ýÀº ¸Þ½ÅÀú RNA¸¦ »ç¿ëÇÏ¿© À¯ÀüÀÚ ¼öÁØ¿¡¼ ÁúȯÀ» ¿¹¹æ ¶Ç´Â Ä¡·áÇÒ ¼ö ÀÖ´Â ´Ü¹éÁúÀÇ »ý»êÀ» ¼¼Æ÷¿¡ Áö½ÃÇÔÀ¸·Î½á ±â´ÉÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 5¿ù ¹Ì±¹ Á¦¾à ¹× ¹ÙÀÌ¿À ±â¼ú ±â¾÷ÀÎ Moderna»ç´Â ÇÁ·ÎÇǿ»êÇ÷Áõ¿¡ ´ëÇÑ Ä¡Çè¿ë mRNA ¿ä¹ýÀÎ mRNA-3927ÀÇ 1/2»ó ½ÃÇè Áß°£ µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀº mRNA¸¦ ÅëÇØ PCCA ¹× PCCB À¯ÀüÀÚÀÇ ±â´ÉÀû »çº»À» Àü´ÞÇÏ¿© °£ È¿¼Ò Ȱ¼ºÀ» ȸº¹½ÃŰ°í ´ë»ç¼º ±â´É ÀúÇϸ¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ÃÖ÷´Ü Á¢±Ù¹ýÀº ÁúȯÀÇ À¯ÀüÀû ±Ùº» ¿øÀο¡ ´ëóÇÔÀ¸·Î½á ȯÀÚÀÇ Àü±Í¸¦ °³¼±Çϰí, ÀÌ Èñ±ÍÇÑ ´ë»ç¼º Áúȯ¿¡ °É¸° »ç¶÷µé¿¡°Ô »õ·Î¿î Èñ¸ÁÀ» Á¦°øÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå Æ¯Â¡
Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«
Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À
Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ)
- ÃÖÁ¾ ÀÌ¿ë »ê¾÷ÀÇ ºÐ¼®
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : ¼ºÀå·ü ºÐ¼®
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå ½ÇÀû : ±Ô¸ð ¹× ¼ºÀå(2019-2024³â)
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå ¿¹Ãø : ±Ô¸ð ¹× ¼ºÀå(2024-2029³â, 2034³â)
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ Àüü ½ÃÀå ±Ô¸ð(TAM)
Á¦6Àå ½ÃÀå ¼¼ºÐÈ
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº° ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
- L-Ä«¸£´Ïƾ
- Ç×»ýÁ¦
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : Åõ¿© °æ·Îº° ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
- °æ±¸
- Á¤¸Æ³»
- ±ÙÀ°³»
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : À¯Åë ä³Îº° ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : L-Ä«¸£´Ïƾ À¯Çüº° ¼¼ºÐÈ ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
- °æ±¸
- ÁÖ»çÁ¦
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : Ç×»ýÁ¦ À¯Çüº° ¼¼ºÐÈ ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
- °æ±¸
- ÁÖ»çÁ¦
Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : Áö¿ªº° ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
- ¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : ±¹°¡º° ºÐ¼® ¹× ¿¹Ãø(2019-2024³â, 2024-2029³â, 2034³â)
Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
Á¦9Àå Áß±¹ ½ÃÀå
Á¦10Àå Àεµ ½ÃÀå
Á¦11Àå ÀϺ» ½ÃÀå
Á¦12Àå È£ÁÖ ½ÃÀå
Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå
Á¦14Àå Çѱ¹ ½ÃÀå
Á¦15Àå ¼À¯·´ ½ÃÀå
Á¦16Àå ¿µ±¹ ½ÃÀå
Á¦17Àå µ¶ÀÏ ½ÃÀå
Á¦18Àå ÇÁ¶û½º ½ÃÀå
Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå
Á¦20Àå ½ºÆäÀÎ ½ÃÀå
Á¦21Àå µ¿À¯·´ ½ÃÀå
Á¦22Àå ·¯½Ã¾Æ ½ÃÀå
Á¦23Àå ºÏ¹Ì ½ÃÀå
Á¦24Àå ¹Ì±¹ ½ÃÀå
Á¦25Àå ij³ª´Ù ½ÃÀå
Á¦26Àå ³²¹Ì ½ÃÀå
Á¦27Àå ºê¶óÁú ½ÃÀå
Á¦28Àå Áßµ¿ ½ÃÀå
Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå
Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ
- ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : °æÀï ±¸µµ
- ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå : ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Moderna Therapeutics : °³¿ä, Á¦Ç° ¹× ¼ºñ½º, Àü·« ¹× À繫 ºÐ¼®
- Synlogic Therapeutics : °³¿ä, Á¦Ç° ¹× ¼ºñ½º, Àü·« ¹× À繫 ºÐ¼®
- Invitae Corporation : °³¿ä, Á¦Ç° ¹× ¼ºñ½º, Àü·« ¹× À繫 ºÐ¼®
- Global Calcium : °³¿ä, Á¦Ç° ¹× ¼ºñ½º, Àü·« ¹× À繫 ºÐ¼®
- BridgeBio Pharma : °³¿ä, Á¦Ç° ¹× ¼ºñ½º, Àü·« ¹× À繫 ºÐ¼®
Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷
- AdvaCare Pharma
- HemoShear Therapeutics
- DNA Labs
- Velnex Medicare
- Phytologix Life Scieneces
- Liaoning Koncepnutra Co. Ltd.
- Propionic Acidemia Foundation
- Agex Pharma
- Gladfem
- CSL Behring
- Octapharma AG
- Sanquin
- Kedrion SpA
- Shire plc
- Vitane Pharmaceuticals Inc.
Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå
Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)
Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ
Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«
- ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
- ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
- ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå(2029³â) : ¼ºÀå Àü·«
- ½ÃÀå µ¿Çâ¿¡ ±âÃÊÇÑ Àü·«
- °æÀï Àü·«
Á¦36Àå ºÎ·Ï
AJY
Propionic acidemia (PA) is a rare inherited metabolic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase, which is crucial for breaking down specific amino acids and fatty acids. This deficiency results in the accumulation of toxic compounds in the blood, leading to severe symptoms such as metabolic crises and neurological damage. If left untreated, the condition can be life-threatening, particularly during infancy.
The primary drug classes used for treating propionic acidemia include L-carnitine and antibiotics. L-Carnitine is a naturally occurring compound that plays a vital role in transporting long-chain fatty acids into mitochondria, where they undergo oxidation to generate energy. Treatment can be administered through various routes, including oral, intravenous, and intramuscular methods. These medications are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.
The propionic acidemia market research report is one of a series of new reports from The Business Research Company that provides propionic acidemia market statistics, including propionic acidemia industry global market size, regional shares, competitors with a propionic acidemia market share, detailed propionic acidemia market segments, market trends and opportunities, and any further data you may need to thrive in the propionic acidemia industry. This propionic acidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The propionic acidemia market size has grown steadily in recent years. It will grow from $2.00 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to factors such as the increasing prevalence of the disease, expansion of newborn screening programs, rising healthcare expenditures, a higher rate of pediatric diagnoses, and the advancement of rare disease initiatives.
The propionic acidemia market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The projected growth during the forecast period can be attributed to factors such as expanding awareness campaigns, a rising number of metabolic disorder cases, increased adoption of telemedicine, growing demand for personalized treatments, and increased healthcare investments. Key trends expected in this period include technological advancements in diagnostics, the development of gene therapies, innovations in metabolic treatments, the integration of AI in healthcare, and the creation of novel therapeutics.
The increasing prevalence of genetic disorders is expected to drive the growth of the propionic acidemia market. Genetic disorders are conditions caused by mutations or abnormalities in an individual's DNA, which may be inherited or occur spontaneously, impacting health and development. One of the key factors contributing to the rise in genetic disorders is consanguineous marriages, which increase the likelihood of inheriting recessive genetic mutations. This occurs when defective genes are passed down from both parents, significantly raising the risk of genetic conditions. Propionic acidemia plays a crucial role in managing genetic disorders by providing targeted treatments that address metabolic imbalances and improve patient outcomes. For example, in July 2022, a report published by the Cystic Fibrosis (CF) Foundation, a US-based non-profit organization, indicated that the prevalence of cystic fibrosis had increased, affecting nearly 40,000 children and adults in the United States in 2022, with over 105,000 individuals diagnosed globally. Consequently, the growing prevalence of genetic disorders is fueling the expansion of the propionic acidemia market.
Leading companies in the propionic acidemia market are focusing on the development of innovative mRNA-based treatments to directly target the genetic causes of the disease. mRNA therapies function by using messenger RNA to instruct cells to produce proteins that can prevent or treat diseases at the genetic level. For example, in May 2023, Moderna, a US-based pharmaceutical and biotechnology company, shared interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia. This therapy delivers functional copies of the PCCA and PCCB genes via mRNA, restoring enzyme activity in the liver and potentially reducing metabolic decompensations. This cutting-edge approach aims to enhance patient outcomes by addressing the genetic root cause of the disease, offering new hope for those affected by this rare metabolic disorder.
In May 2023, Ironwood Pharmaceuticals Inc., a US-based biotechnology company, acquired VectivBio for approximately $1 billion. Through this acquisition, Ironwood aims to strengthen its pipeline for rare diseases by integrating VectivBio's innovative therapies, including investigational treatments for propionic acidemia. VectivBio, a Switzerland-based biotechnology company, specializes in developing treatments for rare gastrointestinal and metabolic disorders.
Major players in the propionic acidemia market are Moderna Therapeutics, Synlogic Therapeutics, Invitae Corporation, Global Calcium, BridgeBio Pharma, AdvaCare Pharma, HemoShear Therapeutics, DNA Labs, Velnex Medicare, Phytologix Life Scieneces, Liaoning Koncepnutra Co. Ltd., Propionic Acidemia Foundation, Agex Pharma, Gladfem, CSL Behring, Octapharma AG, Sanquin, Kedrion SpA, Shire plc, Vitane Pharmaceuticals Inc.
North America was the largest region in the propionic acidemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in propionic acidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the propionic acidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The propionic acidemia market includes revenues earned by entities through enzyme replacement therapy (ERT), nutritional therapy services, personalized care management services, patient support programs, and pharmacogenomic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Propionic Acidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on propionic acidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for propionic acidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The propionic acidemia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: L-Carnitine; Antibiotics
- 2) By Route of Administration: Oral; Intravenous; Intramuscular
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Sub Segments:
- 1) By L-Carnitine Drug Class: Oral L-Carnitine; Injectable L-Carnitine
- 2) By Antibiotics Drug Class: Oral Antibiotics; Injectable Antibiotics
- Companies Mentioned: Moderna Therapeutics; Synlogic Therapeutics; Invitae Corporation; Global Calcium; BridgeBio Pharma
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Propionic Acidemia Market Characteristics
3. Propionic Acidemia Market Trends And Strategies
4. Propionic Acidemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Propionic Acidemia Growth Analysis And Strategic Analysis Framework
- 5.1. Global Propionic Acidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Propionic Acidemia Market Growth Rate Analysis
- 5.4. Global Propionic Acidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Propionic Acidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Propionic Acidemia Total Addressable Market (TAM)
6. Propionic Acidemia Market Segmentation
- 6.1. Global Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- L-Carnitine
- Antibiotics
- 6.2. Global Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous
- Intramuscular
- 6.3. Global Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Propionic Acidemia Market, Sub-Segmentation Of L-Carnitine, By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- 6.5. Global Propionic Acidemia Market, Sub-Segmentation Of Antibiotics, By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
7. Propionic Acidemia Market Regional And Country Analysis
- 7.1. Global Propionic Acidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Propionic Acidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Propionic Acidemia Market
- 8.1. Asia-Pacific Propionic Acidemia Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Propionic Acidemia Market
- 9.1. China Propionic Acidemia Market Overview
- 9.2. China Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Propionic Acidemia Market
- 10.1. India Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Propionic Acidemia Market
- 11.1. Japan Propionic Acidemia Market Overview
- 11.2. Japan Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Propionic Acidemia Market
- 12.1. Australia Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Propionic Acidemia Market
- 13.1. Indonesia Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Propionic Acidemia Market
- 14.1. South Korea Propionic Acidemia Market Overview
- 14.2. South Korea Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Propionic Acidemia Market
- 15.1. Western Europe Propionic Acidemia Market Overview
- 15.2. Western Europe Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Propionic Acidemia Market
- 16.1. UK Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Propionic Acidemia Market
- 17.1. Germany Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Propionic Acidemia Market
- 18.1. France Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Propionic Acidemia Market
- 19.1. Italy Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Propionic Acidemia Market
- 20.1. Spain Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Propionic Acidemia Market
- 21.1. Eastern Europe Propionic Acidemia Market Overview
- 21.2. Eastern Europe Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Propionic Acidemia Market
- 22.1. Russia Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Propionic Acidemia Market
- 23.1. North America Propionic Acidemia Market Overview
- 23.2. North America Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Propionic Acidemia Market
- 24.1. USA Propionic Acidemia Market Overview
- 24.2. USA Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Propionic Acidemia Market
- 25.1. Canada Propionic Acidemia Market Overview
- 25.2. Canada Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Propionic Acidemia Market
- 26.1. South America Propionic Acidemia Market Overview
- 26.2. South America Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Propionic Acidemia Market
- 27.1. Brazil Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Propionic Acidemia Market
- 28.1. Middle East Propionic Acidemia Market Overview
- 28.2. Middle East Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Propionic Acidemia Market
- 29.1. Africa Propionic Acidemia Market Overview
- 29.2. Africa Propionic Acidemia Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Propionic Acidemia Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Propionic Acidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Propionic Acidemia Market Competitive Landscape And Company Profiles
- 30.1. Propionic Acidemia Market Competitive Landscape
- 30.2. Propionic Acidemia Market Company Profiles
- 30.2.1. Moderna Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Synlogic Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Invitae Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Global Calcium Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. BridgeBio Pharma Overview, Products and Services, Strategy and Financial Analysis
31. Propionic Acidemia Market Other Major And Innovative Companies
- 31.1. AdvaCare Pharma
- 31.2. HemoShear Therapeutics
- 31.3. DNA Labs
- 31.4. Velnex Medicare
- 31.5. Phytologix Life Scieneces
- 31.6. Liaoning Koncepnutra Co. Ltd.
- 31.7. Propionic Acidemia Foundation
- 31.8. Agex Pharma
- 31.9. Gladfem
- 31.10. CSL Behring
- 31.11. Octapharma AG
- 31.12. Sanquin
- 31.13. Kedrion SpA
- 31.14. Shire plc
- 31.15. Vitane Pharmaceuticals Inc.
32. Global Propionic Acidemia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Propionic Acidemia Market
34. Recent Developments In The Propionic Acidemia Market
35. Propionic Acidemia Market High Potential Countries, Segments and Strategies
- 35.1 Propionic Acidemia Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Propionic Acidemia Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Propionic Acidemia Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer